首页 >
法规速递
-
Document: Agenda of the COMP meeting 9-11 September 2025-2025/9/9
2025-09-10查看详情 > -
Document: Respiporc Flu3 : EPAR - Scientific Discussion-2025/10/14
2025-10-15查看详情 > -
Document: EMA health threats plan-2025/11/18
2025-11-19查看详情 > -
Document: Questions and answers on the Union list of critical medicines-2025/12/12
2025-12-15查看详情 > -
鼓励药物研发创新 提升审评审批质效——新条例助推医药产业新发展-2026/1/27
2026-01-28查看详情 > -
Document: Records of data processing activity for the handling the contribution towards commuting costs-2026/3/4
2026-03-05查看详情 > -
Document: European Medicines Agency’s data protection notice for the exchange of information during the Critical Medicines Vulnerability Assessment exercise-2026/4/1
2026-04-02查看详情 > -
国家药监局关于恢复销售使用印度瑞迪博士实验室有限公司富马酸喹硫平的公告（2023年第79号）-2023/6/20
2023-06-21查看详情 > -
Draft Guidance: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act - Revision 2-2023/12/6
2023-12-21查看详情 > -
Document: CHMP and Rapporteurs' assessment report template on Similarity Rev. 03.23-2025/1/22
2025-01-23查看详情 >
